drugset / Trial / NCT02708186

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)

NCT02708186 ↗

Phase 2 Completed 34 enrolled Axovant Sciences Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study seeks to evaluate the safety and efficacy of Nelotanserin for the treatment of Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with dementia with Lewy bodies (DLB) or Parkinson's disease dementia (PDD).

Timeline

Start
2016-03
Primary completion
2018-05
Completion
2018-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Nelotanserin Small molecule 80 mg Oral